logo-loader
viewFutura Medical PLC

Futura Medical's James Barder says regulatory submissions for MED3000 remain on track

Futura Medical PLC's (LON:FUM) James Barder tells Proactive London's Andrew Scott they've seen little impact from the coronavirus lockdown and that regulatory submissions for its erectile dysfunction treatment remain on track.

The treatment is MED3000 - a fast-acting gel that will be targeted at men for whom the current treatments don’t work.

Barder says a second pre-submission meeting with the US Food & Drug Administration has been now set.

Quick facts: Futura Medical PLC

Price: 17.88 GBX

AIM:FUM
Market: AIM
Market Cap: £43.92 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Futura Medical PLC named herein, including the promotion by the Company of Futura Medical PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Futura Medical assessing commercialisation options for CBD100

Futura Medical's (LON:FUM) James Barder speaks to Proactive London's Andrew Scott following the news they've completed initial laboratory and optimisation work on its Dermasys® cannabidiol gel (CBD100). He says the studies have demonstrated highly efficient penetration of cannabidiol into and...

1 week ago

2 min read